Contineum Therapeutics, Inc.
CTNM
$4.76
$1.1130.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.40M | 4.54M | 3.47M | 3.04M | 2.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.11M | 17.05M | 12.97M | 10.94M | 9.93M |
| Operating Income | -18.11M | -17.05M | -12.97M | -10.94M | -9.93M |
| Income Before Tax | -15.99M | -14.57M | -10.27M | -9.01M | -8.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.99M | -14.57M | -10.27M | -9.01M | -8.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.99M | -14.57M | -10.27M | -9.01M | -8.42M |
| EBIT | -18.11M | -17.05M | -12.97M | -10.94M | -9.93M |
| EBITDA | -18.03M | -16.97M | -12.91M | -10.88M | -9.87M |
| EPS Basic | -0.62 | -0.56 | -0.40 | -0.39 | -3.55 |
| Normalized Basic EPS | -0.39 | -0.35 | -0.25 | -0.24 | -2.22 |
| EPS Diluted | -0.62 | -0.56 | -0.40 | -0.39 | -3.55 |
| Normalized Diluted EPS | -0.39 | -0.35 | -0.25 | -0.24 | -2.22 |
| Average Basic Shares Outstanding | 25.87M | 25.82M | 25.73M | 23.36M | 2.37M |
| Average Diluted Shares Outstanding | 25.87M | 25.82M | 25.73M | 23.36M | 2.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |